CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Reminder - Five CTS Forms will be updated on Monday September 2, 2019. Some of the forms are posted ...
The new online Learning Center with new content can still be found under the “Training” folder on ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...